Skip to main content


Competition Law and Intellectual Property Go Another Round

7 July 2010
IP Frontline
In a new judgment that further explores the application of competition law to intellectual property rights, the EU General Court has upheld a 2005 Commission decision finding that AstraZeneca1 abused a marketdominant position by blocking or delaying the entry of generic versions of its ulcer drug Losec2.  However, the Court has also reduced to €52.5 million the €60 million fine originally imposed on AstraZeneca, reflecting the Commission’s failure to prove one element of its case.


Nathalie Jalabert Doury, Kiran Desai and Jens Peter Schmidt
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.